|
1
|
Iskander KN, Osuchowski MF,
Stearns-Kurosawa DJ, Kurosawa S, Stepien D, Valentine C and Remick
DG: Sepsis: Multiple abnormalities, heterogeneous responses, and
evolving understanding. Physiol Rev. 93:1247–1288. 2013. View Article : Google Scholar :
|
|
2
|
Edman-Wallér J, Ljungström L, Jacobsson G,
Andersson R and Werner M: Systemic symptoms predict presence or
development of severe sepsis and septic shock. Infect Dis (Lond).
48:209–214. 2016. View Article : Google Scholar
|
|
3
|
Mayeux PR and MacMillan-Crow LA:
Pharmacological targets in the renal peritubular microenvironment:
Implications for therapy for sepsis-induced acute kidney injury.
Pharmacol Ther. 134:139–155. 2012. View Article : Google Scholar :
|
|
4
|
Gill SE, Taneja R, Rohan M, Wang L and
Mehta S: Pulmonary microvascular albumin leak is associated with
endothelial cell death in murine sepsis-induced lung injury in
vivo. PLoS One. 9:e885012014. View Article : Google Scholar :
|
|
5
|
Crouser E, Exline M, Knoell D and Wewers
MD: Sepsis: Links between pathogen sensing and organ damage. Curr
Pharm Des. 14:1840–1852. 2008. View Article : Google Scholar :
|
|
6
|
de Pablo R, Monserrat J, Prieto A and
Alvarez-Mon M: Role of circulating lymphocytes in patients with
sepsis. Biomed Res Int. 2014:6710872014. View Article : Google Scholar :
|
|
7
|
Hotchkiss RS and Karl IE: The
pathophysiology and treatment of sepsis. N Engl J Med. 348:138–150.
2003. View Article : Google Scholar
|
|
8
|
Sakr Y, Vincent JL, Ruokonen E,
Pizzamiglio M, Installe E, Reinhart K and Moreno R: Sepsis
Occurrence in Acutely Ill Patients Investigators: Sepsis and organ
system failure are major determinants of post-intensive care unit
mortality. J Crit Care. 23:475–483. 2008. View Article : Google Scholar
|
|
9
|
Yende S, Waterer GW, Tolley EA, Newman AB,
Bauer DC, Taaffe DR, Jensen R, Crapo R, Rubin S, Nevitt M, et al:
Inflammatory markers are associated with ventilatory limitation and
muscle dysfunction in obstructive lung disease in well functioning
elderly subjects. Thorax. 61:10–16. 2006. View Article : Google Scholar
|
|
10
|
Najafi A, Mojtahedzadeh M, Ahmadi KH,
Abdollahi M, Mousavi M, Chelkeba L, Najmeddin F and Ahmadi A: The
immunological benefit of higher dose N-acetyl cysteine following
mechanical ventilation in critically ill patients. Daru. 22:572014.
View Article : Google Scholar :
|
|
11
|
Yende S, D'Angelo G, Mayr F, Kellum JA,
Weissfeld L, Kaynar AM, Young T, Irani K and Angus DC: GenIMS
Investigators: Elevated hemostasis markers after pneumonia
increases one-year risk of all-cause and cardiovascular deaths.
PLoS One. 6:e228472011. View Article : Google Scholar :
|
|
12
|
Moon SH, Jenkins CM, Liu X, Guan S,
Mancuso DJ and Gross RW: Activation of mitochondrial
calcium-independent phospholipase A2γ (iPLA2γ) by divalent cations
mediating arachidonate release and production of downstream
eicosanoids. J Biol Chem. 287:14880–14895. 2012. View Article : Google Scholar :
|
|
13
|
Dennis EA, Cao J, Hsu YH, Magrioti V and
Kokotos G: Phospholipase A2 enzymes: Physical structure, biological
function, disease implication, chemical inhibition, and therapeutic
intervention. Chem Rev. 111:6130–6185. 2011. View Article : Google Scholar :
|
|
14
|
Stafforini DM, Elstad MR, McIntyre TM,
Zimmerman GA and Prescott SM: Human macrophages secret
platelet-activating factor acetylhydrolase. J Biol Chem.
265:9682–9687. 1990.
|
|
15
|
Tjoelker LW, Wilder C, Eberhardt C,
Stafforini DM, Dietsch G, Schimpf B, Hooper S, Le Trong H, Cousens
LS, Zimmerman GA, et al: Anti-inflammatory properties of a
platelet-activating factor acetylhydrolase. Nature. 374:549–553.
1995. View
Article : Google Scholar
|
|
16
|
Kudo I and Murakami M: Phospholipase A2
enzymes. Prostaglandins Other Lipid Mediat. 68–69:3–58. 2002.
View Article : Google Scholar
|
|
17
|
Menschikowski M, Hagelgans A and Siegert
G: Secretory phospholipase A2 of group IIA: Is it an offensive or a
defensive player during atherosclerosis and other inflammatory
diseases? Prostaglandins Other Lipid Mediat. 79:1–33. 2006.
View Article : Google Scholar
|
|
18
|
Nevalainen TJ, Graham GG and Scott KF:
Antibacterial actions of secreted phospholipases A2. Review.
Biochim Biophys Acta. 1781:1–9. 2008. View Article : Google Scholar
|
|
19
|
Karabina SA, Gora S, Atout R and Ninio E:
Extracellular phospholipases in atherosclerosis. Biochimie.
92:594–600. 2010. View Article : Google Scholar
|
|
20
|
Rosenson RS: Phospholipase A2 inhibition
and atherosclerotic vascular disease: Prospects for targeting
secretory and lipoprotein-associated phospholipase A2 enzymes. Curr
Opin Lipidol. 21:473–480. 2010. View Article : Google Scholar
|
|
21
|
Suckling K: Phospholipase A2s: Developing
drug targets for atherosclerosis. Atherosclerosis. 212:357–366.
2010. View Article : Google Scholar
|
|
22
|
Passacquale G, Di Giosia P and Ferro A:
The role of inflammatory biomarkers in developing targeted
cardiovascular therapies: Lessons from the cardiovascular
inflammation reduction trials. Cardiovasc Res. 109:9–23. 2016.
View Article : Google Scholar
|
|
23
|
Rosenson RS and Stafforini DM: Modulation
of oxidative stress, inflammation, and atherosclerosis by
lipoprotein-associated phospholipase A2. J Lipid Res. 53:1767–1782.
2012. View Article : Google Scholar :
|
|
24
|
Bachelerie F, Ben-Baruch A, Burkhardt AM,
Combadiere C, Farber JM, Graham GJ, Horuk R, Sparre-Ulrich AH,
Locati M, Luster AD, et al: International union of basic and
clinical pharmacology. [corrected]. LXXXIX. Update on the extended
family of chemokine receptors and introducing a new nomenclature
for atypical chemokine receptors. Pharmacol Rev. 66:1–79. 2013.
View Article : Google Scholar
|
|
25
|
Kones R: Molecular sources of residual
cardiovascular risk, clinical signals, and innovative solutions:
Relationship with subclinical disease, undertreatment, and poor
adherence: Implications of new evidence upon optimizing
cardiovascular patient outcomes. Vasc Health Risk Manag. 9:617–670.
2013. View Article : Google Scholar :
|
|
26
|
Zalewski A, Macphee C and Nelson JJ:
Lipoprotein-associated phospholipase A2: A potential therapeutic
target for atherosclerosis. Curr Drug Targets Cardiovasc Haematol
Disord. 5:527–532. 2005. View Article : Google Scholar
|
|
27
|
Macphee CH, Nelson J and Zalewski A: Role
of lipoprotein-associated phospholipase A2 in atherosclerosis and
its potential as a therapeutic target. Curr Opin Pharmacol.
6:154–161. 2006. View Article : Google Scholar
|
|
28
|
Bedirli A, Gokahmetoglu S, Sakrak O,
Soyuer I, Ince O and Sozuer E: Beneficial effects of recombinant
platelet-activating factor acetylhydrolase and BN 52021 on
bacterial translocation in cerulein-induced pancreatitis. Eur Surg
Res. 36:136–141. 2004. View Article : Google Scholar
|
|
29
|
Onyimba JA, Coronado MJ, Garton AE, Kim
JB, Bucek A, Bedja D, Gabrielson KL, Guilarte TR and Fairweather D:
The innate immune response to coxsackievirus B3 predicts
progression to cardiovascular disease and heart failure in male
mice. Biol Sex Differ. 2:22011. View Article : Google Scholar :
|
|
30
|
Hutchings L, Watkinson P, Young JD and
Willett K: Defining multiple organ failure after major trauma: A
comparison of the Denver, Sequential Organ Failure Assessment, and
Marshall scoring systems. J Trauma Acute Care Surg. 82:534–541.
2017. View Article : Google Scholar :
|
|
31
|
Shrestha GS, Kwizera A, Lundeg G, Baelani
JI, Azevedo LCP, Pattnaik R, Haniffa R, Gavrilovic S, Mai NTH,
Kissoon N, et al: International Surviving Sepsis Campaign
guidelines 2016: The perspective from low-income and middle-income
countries. Lancet Infect Dis. 17:893–895. 2017. View Article : Google Scholar
|
|
32
|
Angstwurm MW, Dempfle CE and Spannagl M:
New disseminated intravascular coagulation score: A useful tool to
predict mortality in comparison with Acute Physiology and Chronic
Health Evaluation II and Logistic Organ Dysfunction scores. Crit
Care Med. 314–320; quiz 328. 2006. View Article : Google Scholar
|
|
33
|
Kojima M, Aiboshi J, Shibata M, Kobayashi
T and Otomo Y: Novel role of group VIB Ca2+-independent
phospholipase A2γ in leukocyte-endothelial cell interactions: An
intravital microscopic study in rat mesentery. J Trauma Acute Care
Surg. 79:782–789. 2015. View Article : Google Scholar
|
|
34
|
Wang WY, Li J, Yang D, Xu W, Zha RP and
Wang YP: OxLDL stimulates lipoprotein-associated phospholipase A2
expression in THP-1 monocytes via PI3K and p38 MAPK pathways.
Cardiovasc Res. 85:845–852. 2010. View Article : Google Scholar
|
|
35
|
Zhang KJ, Zhang DL, Jiao XL and Dong C:
Effect of phospholipase A2 silencing on acute experimental
pancreatitis. Eur Rev Med Pharmacol Sci. 17:3279–3284. 2013.
|
|
36
|
Isenmann R, Rau B and Beger HG: Early
severe acute pancreatitis: Characteristics of a new subgroup.
Pancreas. 22:274–278. 2001. View Article : Google Scholar
|
|
37
|
Lausevic Z, Lausevic M,
Trbojevic-Stankovic J, Krstic S and Stojimirovic B: Predicting
multiple organ failure in patients with severe trauma. Can J Surg.
51:97–102. 2008.
|
|
38
|
Schuetz P, Amin DN and Greenwald JL: Role
of procalcitonin in managing adult patients with respiratory tract
infections. Chest. 141:1063–1073. 2012. View Article : Google Scholar
|
|
39
|
Becker KL, Snider R and Nylen ES:
Procalcitonin assay in systemic inflammation, infection, and
sepsis: Clinical utility and limitations. Crit Care Med.
36:941–952. 2008. View Article : Google Scholar
|
